Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/162264
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Títol de la revista
Autors
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).
Matèries
Matèries (anglès)
Citació
Citació
VÁZQUEZ CARRERA, Manuel. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. _Trends in Endocrinology and Metabolism_. 2016. Vol. 27, núm. 5, pàgs. 319-334. [consulta: 24 de gener de 2026]. ISSN: 1043-2760. [Disponible a: https://hdl.handle.net/2445/162264]